Please login to the form below
Biogen
This page shows the latest Biogen news and features for those working in and with pharma, biotech and healthcare.
Novartis makes case for gene therapy Zolgensma in SMA
strategy. That came after it evaluated first-to-market SMA gene therapy Spinraza and concluded that the Biogen marketed drug is overpriced.
Latest news
-
Hemlibra off to a flyer as Roche raises 2019 forecasts
There are some big filings due this year – including risdiplam for rare disease spinal muscular atrophy that will take on Biogen’s big-selling Spinraza (nusinersen) – and Roche is also hoping
-
Catalent preps for complex therapy boom with $1.2bn Paragon buy
Last month, Pfizer paid around $640m for a 15% stake in Vivet Therapeutics, while Biogen snapped up Nightstar Therapeutics for $800m and Roche acquired Spark Therapeutics in February for $4.3bn.
-
Gyroscope advances gene therapy platform, merges with Orbit
Biogen for $800m..
-
Biogen’s Spinraza overpriced, says ICER
Expensive rare disease drugs like Biogen’s spinal muscular atrophy (SMA) therapy are “threatening the affordability and sustainability of the US health system”, says ICER. ... The independent US medicines pricing watchdog released a report this
-
Otsuka’s Alzheimer’s agitation drug hits the mark
It may seem a minor victory after the failure of Biogen’s aducanumab in Alzheimer’s disease last week – further diminishing the hope of a therapy that can affect the underlying
More from news
Approximately 103 fully matching, plus 264 partially matching documents found.
Latest Intelligence
-
Where next in Alzheimer’s disease R&D?
Another crushing blow to hopes came on 21 March, when Biogen and Eisai pulled the plug on their phase 3 Abeta-targeting aducanumab. ... N.B. This article was updated on 21 March 2019 following news of Biogen and Eisai's termination of the aducanumab
-
Drug launches to watch in 2019
only other SMA treatment available, Biogen’s Spinraza.
-
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
However, research from RAND and the University of Southern California that was sponsored by Biogen has found that several European countries lack the capacity to rapidly move a disease-modifying treatment
-
Deal Watch October 2018
Samsung Bioepis is a joint venture between Samsung and Biogen Idec; the latter recently (June 2018) invested $700m to bring its stake in the jv to 49.9%.
-
No incentive for a cure
to 12-week course. And Spinraza from Biogen, the first ever disease-modifying treatment for spinal muscular atrophy (SMA), which increases the body’s ability to produce SMN protein critical to.
More from intelligence
Approximately 1 fully matching, plus 36 partially matching documents found.
Latest appointments
-
BMS appoints new commercial leader, Davies joins Eisai and more
operations. She joins Sobi from Biogen, where she served as vice president for global supply chain operations and strategic partnerships.
-
Biogen appoints executive VP, corporate development
Biogen has appointed Daniel Karp as its executive vice president, corporate development effective 11 June. ... He will also become a member of the executive committee and will report directly to chief executive officer Michel Vounatsos, who said: “We
-
Gamida Cell strengthens leadership team
Nee will lead market research, analytics, forecasting, commercial strategies and competitive intelligence at the company, activities he has practised during his time with Biogen, Amgen and Novartis.
-
Editas Medicine names James Mullen as chairman
Before joining Patheon, Mullen served as chief executive officer and president at Biogen and before this he held numerous roles at the biotech.
-
Acumen appoints new strategy director
Thomas Bols will focus on reinforcing Acumen’s healthcare practice
More from appointments
Approximately 16 fully matching, plus 32 partially matching documents found.
Latest from PMHub
-
Healthcircle
Biogen. Chugai. Eisai. Helsinn. Ipsen. Johnson &Johnson. Lundbeck. Medtronic. Mentholatum. Novartis.
-
Attigo (part of the Mednet Group)
Alzheimer’s Research UK. Alzheimer’s Society. Basic Needs. Biogen. Butterfly Scheme. Cardiomyopathy UK.
-
IGNIFI
Allergan . Biogen . Boehringer Ingelheim . Danone Nutricia . Ferring Pharmaceuticals . MSD Healthcare Services .
-
Wallace Health
Our expertise spans healthcare providers, pharmaceuticals and consumer health and we work for clients including HCA Hospitals, Alliance Medical, GSK and Biogen as well as high-performing start-ups such as
-
Bedrock Healthcare Communications
Abbvie. Baxalta. Baxter. Biogen. BMS. Britannia. CareFusion. Celgene. Ipsen. Janssen. Novartis.
More from PMHub
Approximately 1 fully matching, plus 11 partially matching documents found.
Featured jobs
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Experienced / Senior Account Director - Publications - London
-
Up to £80, 000 plus great benefits
-
Senior Medical Writer
-
Competitive salary and benefits
- Senior Account Director/ Associate Director- Pharma and Life Sci...
-
Competitive salary and benefits
- Account Manager / Senior Account Manager - Healthcare Advertisin...
-
Excellent Remuneration
-
Senior Medical Writer
-
Salary TBC
-
Director – Healthcare PR
-
Salary TBC
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Freelance Medical Writer - Healthcare Advertising - London
-
Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day
- Senior Account Manager- Pharma and Life Scienes
-
Competitive salary and benefits
- Project Manager - Medical Communications – South Wales
-
Excellent Remuneration Package
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Project Manager - Digital Healthcare - London
-
Excellent Remuneration Package
-
Account Director, Medical Education
-
Salary TBC
- Senior / Principal Medical Writer - MedComms - Home Based / Vari...
-
Excellent Remuneration Packages
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
Subscribe to our email news alerts
- With Spiriva under pressure, Boehringer moves to bolster pipeline
- Genfit claims FDA breakthrough status for liver disease drug
- Mereo’s shareholders back OncoMed takeover
- Lucid Group announces the appointment of new CFO
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- Q&A: Niels Lund
Latest intelligence
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- How pharma is progressing their commitment in patient engagement...
- Cuttsy+Cuttsy awarded CPD Platinum by the IPA
- Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
- Breaking Bad
- Six behaviours separate the good brand teams from the bad...
Quick links
Infographics
